Anti-RSV Antibody, fusion protein, all type A, B strains, clone 131-2A

RSV is a labile paramyxovirus that produces a characteristic fusion of human cells in tissue culture--the syncytial effect. Two subtypes, A and B, have been identified. Subtype B are characterized as the asymptomatic strains of the virus. The more severe clinical illnesses involve Subtype A strains.

~70 kDa

A2 RSV virus cell extract

Epitope: all type A & B strains

Anti-RSV Antibody, fusion protein, all type A, B strains, clone 131-2A detects level of Respiratory Syncytial Virus & has been published & validated for use in ELISA, FC, IF & WB.

Indirect immunofluorescence.

ELISA

Immunoblotting: (using purified F protein preparations, clone identified a ~70kDa band, Tripp, RA et al 2003)

Final working dilutions must be determined by end user.

Research Category
Infectious Diseases

Research Sub Category
Infectious Diseases - Viral

Reacts with RSV fusion protein, specifically epitope F1a of RSV F-protein {Sominina AA, et al Vestn Ross Akad Med Nauk. 1995;(9):49-54} found on all A & B strains of RSV.

Format: Purified

Protein A Purified immunoglobulin in 0.02M phosphate, 0.25M NaCl, 0.1% NaN3 pH 7.6

Protein A purified

Maintain for 1 year at 2–8°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Control
RSV Control Slides, Catalogue Number 5012-5

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.